Acerus Reports Fourth Quarter and Full Year 2019 Financial Results

- March 4th, 2020

Acerus Pharmaceuticals reported its financial results for the three and twelve-month period ended December 31, 2019. 

Acerus Pharmaceuticals (TSX:ASP) reported its financial results for the three and twelve-month period ended December 31, 2019.

As quoted in the press release:

2019 Highlights

  • Amended and restated (“A&R”) partnership agreement with Aytu Bioscience (“Aytu”) becomes fully functional which should allow for accelerated growth of NATESTO® in the United States

  • Multiple scientific publications and congress presentations highlighting the unique clinical profile of NATESTO®

  • Avanafil New Drug Submission filed with Health Canada

  • Multiple financing transactions in 2019 and 2020 raising over $30 million to fund future growth

Click here to read the full press release.

  Life Science and Healthcare Investing in 2020 report cover

Life Science and Healthcare Investing in 2020

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2020 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply